Monoclonal Anti-PLEKHA7 antibody produced in mouse

Monoclonal Anti-PLEKHA7 (mouse IgG2a isotype) is derived from the hybridoma PLK7 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to a sequence at the N-terminal region of human PLEKHA7, conjugated to KLH. PLEKHA7 contains WW (rsp5-domain), PH (pleckstrin homology), and CC (coiled-coil) domains.

PLEKHA7 (Pleckstrin homology domain containing, family A member 7) is an adherens junction protein localized at the adherens junctions in colonic epithelial cells.

synthetic peptide corresponding to a sequence at the N-terminal region of human PLEKHA7

Monoclonal Anti-PLEKHA7 antibody has been used in

• immunoblotting
• immunocytochemistry
• flow cytometry

Overexpression of PLEKHA7 was reported to be common in invasive lobular carcinomas (ILCs) and hence PLEKHA7 could serve as a molecular marker to differentiate ILCs from invasive ductal carcinomas (IDCs).

PLEKHA7 (Pleckstrin homology domain containing, family A member 7) functions as a cytoplasmic component of the epithelial adherens junction belt, with a subcellular localization and tissue distribution and connects E-cadherin-p120 ctn complex to the microtubule cytoskeleton. It has been reported that PLEKHA7 acts as zonula adherens (ZA) component, identifies Nezha, which further binds to microtubules (MTs) of the cytoskeleton, and forms a protein complex during cytoskeleton assembly.

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.